Iron status influences non-alcoholic fatty liver disease in obesity through the gut microbiome.
Ferritin
Gut microbiome
Iron status
Metagenomics
Non-alcoholic fatty liver disease
Obesity
Shotgun sequencing
Systems medicine
Journal
Microbiome
ISSN: 2049-2618
Titre abrégé: Microbiome
Pays: England
ID NLM: 101615147
Informations de publication
Date de publication:
07 05 2021
07 05 2021
Historique:
received:
13
10
2020
accepted:
18
03
2021
entrez:
8
5
2021
pubmed:
9
5
2021
medline:
20
5
2021
Statut:
epublish
Résumé
The gut microbiome and iron status are known to play a role in the pathophysiology of non-alcoholic fatty liver disease (NAFLD), although their complex interaction remains unclear. Here, we applied an integrative systems medicine approach (faecal metagenomics, plasma and urine metabolomics, hepatic transcriptomics) in 2 well-characterised human cohorts of subjects with obesity (discovery n = 49 and validation n = 628) and an independent cohort formed by both individuals with and without obesity (n = 130), combined with in vitro and animal models. Serum ferritin levels, as a markers of liver iron stores, were positively associated with liver fat accumulation in parallel with lower gut microbial gene richness, composition and functionality. Specifically, ferritin had strong negative associations with the Pasteurellaceae, Leuconostocaceae and Micrococcaea families. It also had consistent negative associations with several Veillonella, Bifidobacterium and Lactobacillus species, but positive associations with Bacteroides and Prevotella spp. Notably, the ferritin-associated bacterial families had a strong correlation with iron-related liver genes. In addition, several bacterial functions related to iron metabolism (transport, chelation, heme and siderophore biosynthesis) and NAFLD (fatty acid and glutathione biosynthesis) were also associated with the host serum ferritin levels. This iron-related microbiome signature was linked to a transcriptomic and metabolomic signature associated to the degree of liver fat accumulation through hepatic glucose metabolism. In particular, we found a consistent association among serum ferritin, Pasteurellaceae and Micrococcacea families, bacterial functions involved in histidine transport, the host circulating histidine levels and the liver expression of GYS2 and SEC24B. Serum ferritin was also related to bacterial glycine transporters, the host glycine serum levels and the liver expression of glycine transporters. The transcriptomic findings were replicated in human primary hepatocytes, where iron supplementation also led to triglycerides accumulation and induced the expression of lipid and iron metabolism genes in synergy with palmitic acid. We further explored the direct impact of the microbiome on iron metabolism and liver fact accumulation through transplantation of faecal microbiota into recipient's mice. In line with the results in humans, transplantation from 'high ferritin donors' resulted in alterations in several genes related to iron metabolism and fatty acid accumulation in recipient's mice. Altogether, a significant interplay among the gut microbiome, iron status and liver fat accumulation is revealed, with potential significance for target therapies. Video abstract.
Sections du résumé
BACKGROUND
The gut microbiome and iron status are known to play a role in the pathophysiology of non-alcoholic fatty liver disease (NAFLD), although their complex interaction remains unclear.
RESULTS
Here, we applied an integrative systems medicine approach (faecal metagenomics, plasma and urine metabolomics, hepatic transcriptomics) in 2 well-characterised human cohorts of subjects with obesity (discovery n = 49 and validation n = 628) and an independent cohort formed by both individuals with and without obesity (n = 130), combined with in vitro and animal models. Serum ferritin levels, as a markers of liver iron stores, were positively associated with liver fat accumulation in parallel with lower gut microbial gene richness, composition and functionality. Specifically, ferritin had strong negative associations with the Pasteurellaceae, Leuconostocaceae and Micrococcaea families. It also had consistent negative associations with several Veillonella, Bifidobacterium and Lactobacillus species, but positive associations with Bacteroides and Prevotella spp. Notably, the ferritin-associated bacterial families had a strong correlation with iron-related liver genes. In addition, several bacterial functions related to iron metabolism (transport, chelation, heme and siderophore biosynthesis) and NAFLD (fatty acid and glutathione biosynthesis) were also associated with the host serum ferritin levels. This iron-related microbiome signature was linked to a transcriptomic and metabolomic signature associated to the degree of liver fat accumulation through hepatic glucose metabolism. In particular, we found a consistent association among serum ferritin, Pasteurellaceae and Micrococcacea families, bacterial functions involved in histidine transport, the host circulating histidine levels and the liver expression of GYS2 and SEC24B. Serum ferritin was also related to bacterial glycine transporters, the host glycine serum levels and the liver expression of glycine transporters. The transcriptomic findings were replicated in human primary hepatocytes, where iron supplementation also led to triglycerides accumulation and induced the expression of lipid and iron metabolism genes in synergy with palmitic acid. We further explored the direct impact of the microbiome on iron metabolism and liver fact accumulation through transplantation of faecal microbiota into recipient's mice. In line with the results in humans, transplantation from 'high ferritin donors' resulted in alterations in several genes related to iron metabolism and fatty acid accumulation in recipient's mice.
CONCLUSIONS
Altogether, a significant interplay among the gut microbiome, iron status and liver fat accumulation is revealed, with potential significance for target therapies. Video abstract.
Identifiants
pubmed: 33962692
doi: 10.1186/s40168-021-01052-7
pii: 10.1186/s40168-021-01052-7
pmc: PMC8106161
doi:
Substances chimiques
Iron
E1UOL152H7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Video-Audio Media
Langues
eng
Sous-ensembles de citation
IM
Pagination
104Subventions
Organisme : Medical Research Council
ID : MR/L01632X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M501797/1
Pays : United Kingdom
Références
Antioxid Redox Signal. 2013 Sep 20;19(9):1026-35
pubmed: 23249217
Annu Rev Immunol. 2011;29:415-45
pubmed: 21219177
Am J Physiol Gastrointest Liver Physiol. 2018 May 1;314(5):G597-G609
pubmed: 29420067
Glia. 2015 Oct;63(10):1738-52
pubmed: 25903009
Diabetes. 2013 Jul;62(7):2266-77
pubmed: 23474485
Hepatology. 2021 Jan;73(1):126-143
pubmed: 32794259
Cell Metab. 2011 Dec 7;14(6):804-10
pubmed: 22152305
J Gastroenterol. 2020 Feb;55(2):142-158
pubmed: 31845054
Cell Metab. 2017 May 2;25(5):1054-1062.e5
pubmed: 28467925
J Hepatol. 2009 Feb;50(2):249-51
pubmed: 19070915
Nat Med. 2018 Jul;24(7):1070-1080
pubmed: 29942096
Front Microbiol. 2017 Dec 12;8:2431
pubmed: 29312162
J Hepatol. 2018 Oct;69(4):927-947
pubmed: 29940269
Crit Rev Biochem Mol Biol. 2017 Jun;52(3):314-326
pubmed: 28276700
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
Int J Biol Macromol. 2020 Feb 15;145:1208-1218
pubmed: 31726162
Genome Biol. 2014;15(12):550
pubmed: 25516281
J Biol Chem. 2017 Jun 23;292(25):10455-10464
pubmed: 28483921
Clin Chem. 2018 Feb;64(2):374-385
pubmed: 29038157
Cell. 2017 Jan 26;168(3):344-361
pubmed: 28129536
J Trace Elem Med Biol. 2018 May;47:12-20
pubmed: 29544798
Biomedicines. 2020 Aug 03;8(8):
pubmed: 32756350
Nature. 2014 Jan 23;505(7484):559-63
pubmed: 24336217
Nucleic Acids Res. 2009 Jan;37(Database issue):D623-8
pubmed: 18940869
Int J Obes (Lond). 2017 Apr;41(4):620-630
pubmed: 28119530
Gastroenterology. 2014 Apr;146(4):1060-9
pubmed: 24361124
Mol Syst Biol. 2017 Mar 2;13(3):916
pubmed: 28254760
BMC Bioinformatics. 2018 Oct 11;19(1):371
pubmed: 30309317
Mol Metab. 2016 Oct 31;6(1):38-47
pubmed: 28123936
Sci Rep. 2015 Sep 11;5:13980
pubmed: 26358367
FEMS Microbiol Rev. 2003 Jun;27(2-3):215-37
pubmed: 12829269
Hepatology. 2017 Jan;65(1):350-362
pubmed: 27358174
Nature. 2011 Jun 15;474(7351):327-36
pubmed: 21677749
Clin Nutr. 2021 Jan;40(1):207-216
pubmed: 32536582
Sci Transl Med. 2017 May 17;9(390):
pubmed: 28515336
AJR Am J Roentgenol. 2007 Dec;189(6):W320-3
pubmed: 18029843
Nature. 2013 Aug 29;500(7464):585-8
pubmed: 23985875
Hepatology. 2012 Jan;55(1):77-85
pubmed: 21953442
Hepatology. 2013 Feb;57(2):601-9
pubmed: 23055155
Hepatology. 2016 Mar;63(3):764-75
pubmed: 26600078
Hepatol Commun. 2017 Apr;1(2):122-139
pubmed: 28626835